Diabetestechnik: Vom Pieksen über das Monitoring zum Closed Loop

Seit der ersten Erwähnung der Stoffwechselerkrankung Diabetes mellitus in der Antike hat es enorme Fortschritte gegeben. Die Blutzuckermessung mit Messstreifen rückt heute durch sensorbasierte kontinuierliche Verfahren (CGM) zunehmend in den Hintergrund. Die CGM in Verbindung mit der automatisierten Insulindosierung gehört mittlerweile zur modernen Diabetestherapie.

Publikationsverlauf

Artikel online veröffentlicht:
26. September 2023

• Literatur

• 1 Häring HU, Gallwitz B, Müller-Wieland D. et al. Zeittafel zur Geschichte des Diabetes mellitus. In: Häring, HU, Gallwitz B, Müller-Wieland D et al., Hrsg. Diabetologie in Klinik und Praxis. 6. Aufl. Stuttgart: Thieme; 2011
• 2 Fehling H. Quantitative Bestimmung des Zuckers im Harn. In: Archiv für physiologische Heilkunde. Band 7. Ebner & Seubert, 1848, OCLC 243416698, ZDB-ID 526992-1: 64–73. München: Bayerische Staatsbibliothek (bsb-muenchen.de);
• 3 Sönksen PH, Judd SL, Lowy C. Home monitoring of blood-glucose. Method for improving diabetic control. Lancet 1978; 8067: 729-732 DOI: 10.1016/s0140-6736(78)90854-1.
• 4 Walford S, Gale EA, Allison SP, Tattersall RB. Self-monitoring of blood-glucose. Improvement of diabetic control. Lancet 1978; 8067: 732-735 DOI: 10.1016/s0140-6736(78)90855-3.
• 5 Freckmann G, Kalatz B, Pfeiffer B. et al. Recent advances in continuous glucose monitoring. Exp Clin Endocrinol Diabetes 2001; 109: S347-S357 DOI: 10.1055/s-2001-18594.
• 6 Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. Br Med J 2011; 343: d3805 DOI: 10.1136/bmj.d3805.
• 7 Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Beck RW, Hirsch IB, Laffel L. et al. The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care 2009; 32: 1378-1383 DOI: 10.2337/dc09-0108.
• 8 Heinemann L, Freckmann G, Ehrmann D. et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Lancet 2018; 391: 1367-1377 DOI: 10.1016/S0140-6736(18)30297-6.
• 9 Beck RW, Riddlesworth T, Ruedy K. et al. Diamond Study Group. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. J Am Med Assoc 2017; 317: 371-378 DOI: 10.1001/jama.2016.19975.
• 10 Battelino T, Danne T, Bergenstal RM. et al. Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the International Consensus on Time in Range. Diabetes Care 2019; 42: 1593-1603 DOI: 10.2337/dci19-0028.
• 11 iDCL Trial Research Group. Brown SA, Kovatchev BP, Raghinaru D. et al. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med 2019; 381: 1707-1717 DOI: 10.1056/NEJMoa1907863.
• 12 Bergenstal RM, Garg S, Weinzimer SA. et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. J Am Med Assoc 2016; 316: 1407-1408 DOI: 10.1001/jama.2016.11708.
• 13 Beato-Víbora PI, Gallego-Gamero F, Ambrojo-López A. et al. Rapid improvement in time in range after the implementation of an advanced hybrid closed-loop system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther 2021; 23: 609-615 DOI: 10.1089/dia.2021.0037.
• 14 Diabeloop WP7 Trial Investigators. Benhamou PY, Franc S, Reznik Y. et al. Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trial. Lancet Digit Health 2019; 1: e17-e25 DOI: 10.1016/S2589-7500(19)30003-2.
• 15 APCam11 Consortium. Tauschmann M, Thabit H, Bally L. et al. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. Lancet 2018; 392: 1321-1329 DOI: 10.1016/S0140-6736(18)31947-0.
• 16 Russell SJ, El-Khatib FH, Sinha M. et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med 2014; 371: 313-325 DOI: 10.1056/NEJMoa1314474.
• 17 El-Khatib FH, Balliro C, Hillard MA. et al. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. Lancet 2017; 389: 369-380 DOI: 10.1016/S0140-6736(16)32567-3.
• 18 Castellanos LE, Balliro CA, Sherwood JS. et al. Performance of the insulin-only iLet Bionic Pancreas and the bihormonal iLet using dasiglucagon in adults with type 1 diabetes in a home-use setting. Diabetes Care 2021; 44: e118-e120 DOI: 10.2337/dc20-1086.